ecropolis

Antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron | Structural brain changes in post-acute COVID-19 patients | Persistent post–COVID-19 smell loss | Persistent symptoms and sequelae after SARS-CoV-2 infection | VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19 | Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System | Molnupiravir plus usual care versus usual care alone as early treatment for adults | Higher dose corticosteroids in hospitalized COVID-19 patients | FDA approves Roche’s Actemra (tocilizumab) for the treatment of COVID-19 | Outpatient treatment of Covid-19 with metformin, ivermectin, and fluvoxamine | Canine real-time detection of SARS-CoV-2 infections | Clinical Validation of a Novel T-Cell Receptor | Modelling the adjustment of COVID-19 response | Two masks can be worse than one: N95 respirator failure caused by an overlying face mask | Airflow Patterns in Double-Occupancy Patient Rooms | The epidemiology of long COVID in US adults

Immunological dysfunction persists for 8 months |
Clinical Features and Burden of Post-Acute Sequelae of SARS-CoV-2 Infection |
Demonstration of stable clusters of symptoms | Longitudinal Analysis of T cells in COVID-19 |
Reconsideration of anti-nucleocapsid IgG antibody | Early Estimates of Bivalent mRNA Vaccine |
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated
Hospitalization | Effect of Nirmatrelvir/Ritonavir versus Placebo on COVID-19─Related Hospitalizations |
COVID-19 Convalescent Plasma Outpatient Therapy | Bacterial Co-infection and Empirical Antibiotic Therapy in Patients |
Similar SARS-CoV-2 Ct value distributions in anterior nares versus nasopharyngeal samples |
Prevalence of SARS-CoV-2 and Influenza Coinfection and Clinical Characteristics | The WHO estimates of excess mortality associated with the COVID-19 pandemic |
Impact of SARS-CoV-2 variants on inpatient clinical outcome | Association of Time to Surgery After COVID-19 Infection